File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*

TitleIntermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*
Authors
KeywordsCardiac magnetic resonance imaging T2* (MRI T2*)
Chelation protocol
Combined therapy
Deferiprone (L1)
Deferoxamine(DFO)
Serum ferritin(SF)
Thalassemia
Issue Date2011
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03630269.asp
Citation
Hemoglobin, 2011, v. 35 n. 3, p. 199-205 How to Cite?
AbstractA standardized chelation protocol was applied by stratifying transfusion-dependent thalassemic patients into three groups, namely well chelated group (A), inadequately chelated group without (B) or with (C) risk of cardiac complications based on serum ferritin (SF) levels and magnetic resonance imaging (MRI) cardiac T2* measurements. Group A patients were advised to continue with deferoxamine (DFO) (Regimen Ic). Group B patients were given options of either intensification of DFO alone (Regimen Ii), deferiprone (L1) alone (Regimen II) or combined therapy with L1 and DFO (Regimen III). Group C patients were advised to take either Regimen Ii or Regimen III. The 1-year result showed that the combined therapy (Regimen III) significantly reduced SF level, cardiac and liver iron in the groups of inadequately chelated patients. The same set of outcome parameters was repeated at 2.5 years of treatment so as to evaluate the intermediate-term effects of this risk stratified chelation protocol. The number of patients with cardiac T2* <20 ms decreased from 34 (60%) at baseline to 17 (30%) of the whole cohort of 57 patients at the end of the study. There were further improvements in SF, cardiac and liver T2* in Group C patients. Significant improvement in left ventricular ejection fraction (LVEF) was demonstrated after 2.5 years of the combined therapy group in which the change was not initially apparent after the first year of assessment. Copyright © Informa Healthcare USA, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/135331
ISSN
2014 Impact Factor: 0.787
2014 SCImago Journal Rankings: 0.399
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHa, SYen_HK
dc.contributor.authorMok, ASPen_HK
dc.contributor.authorChu, WCWen_HK
dc.contributor.authorRasalkar, DDen_HK
dc.contributor.authorCheuk, DKLen_HK
dc.contributor.authorChiang, AKSen_HK
dc.contributor.authorHo, MHKen_HK
dc.contributor.authorChan, GCFen_HK
dc.date.accessioned2011-07-27T01:33:40Z-
dc.date.available2011-07-27T01:33:40Z-
dc.date.issued2011en_HK
dc.identifier.citationHemoglobin, 2011, v. 35 n. 3, p. 199-205en_HK
dc.identifier.issn0363-0269en_HK
dc.identifier.urihttp://hdl.handle.net/10722/135331-
dc.description.abstractA standardized chelation protocol was applied by stratifying transfusion-dependent thalassemic patients into three groups, namely well chelated group (A), inadequately chelated group without (B) or with (C) risk of cardiac complications based on serum ferritin (SF) levels and magnetic resonance imaging (MRI) cardiac T2* measurements. Group A patients were advised to continue with deferoxamine (DFO) (Regimen Ic). Group B patients were given options of either intensification of DFO alone (Regimen Ii), deferiprone (L1) alone (Regimen II) or combined therapy with L1 and DFO (Regimen III). Group C patients were advised to take either Regimen Ii or Regimen III. The 1-year result showed that the combined therapy (Regimen III) significantly reduced SF level, cardiac and liver iron in the groups of inadequately chelated patients. The same set of outcome parameters was repeated at 2.5 years of treatment so as to evaluate the intermediate-term effects of this risk stratified chelation protocol. The number of patients with cardiac T2* <20 ms decreased from 34 (60%) at baseline to 17 (30%) of the whole cohort of 57 patients at the end of the study. There were further improvements in SF, cardiac and liver T2* in Group C patients. Significant improvement in left ventricular ejection fraction (LVEF) was demonstrated after 2.5 years of the combined therapy group in which the change was not initially apparent after the first year of assessment. Copyright © Informa Healthcare USA, Inc.en_HK
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03630269.aspen_HK
dc.relation.ispartofHemoglobinen_HK
dc.rightsHemoglobin. Copyright © Informa Healthcare.-
dc.subjectCardiac magnetic resonance imaging T2* (MRI T2*)en_HK
dc.subjectChelation protocolen_HK
dc.subjectCombined therapyen_HK
dc.subjectDeferiprone (L1)en_HK
dc.subjectDeferoxamine(DFO)en_HK
dc.subjectSerum ferritin(SF)en_HK
dc.subjectThalassemiaen_HK
dc.subject.meshChelation Therapy - methods-
dc.subject.meshHeart Diseases - diagnosis - etiology - prevention and control-
dc.subject.meshIron Chelating Agents - therapeutic use-
dc.subject.meshMagnetic Resonance Imaging - methods-
dc.subject.meshbeta-Thalassemia - complications - drug therapy-
dc.titleIntermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*en_HK
dc.typeConference_Paperen_HK
dc.identifier.emailChiang, AKS:chiangak@hkucc.hku.hken_HK
dc.identifier.emailChan, GCF:gcfchan@hkucc.hku.hken_HK
dc.identifier.authorityChiang, AKS=rp00403en_HK
dc.identifier.authorityChan, GCF=rp00431en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.3109/03630269.2011.579007en_HK
dc.identifier.pmid21599432en_HK
dc.identifier.scopuseid_2-s2.0-79957467894en_HK
dc.identifier.hkuros186807en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79957467894&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume35en_HK
dc.identifier.issue3en_HK
dc.identifier.spage199en_HK
dc.identifier.epage205en_HK
dc.identifier.isiWOS:000290797500003-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridHa, SY=7202501115en_HK
dc.identifier.scopusauthoridMok, ASP=24470317700en_HK
dc.identifier.scopusauthoridChu, WCW=7402227871en_HK
dc.identifier.scopusauthoridRasalkar, DD=15837937400en_HK
dc.identifier.scopusauthoridCheuk, DKL=8705936100en_HK
dc.identifier.scopusauthoridChiang, AKS=7101623534en_HK
dc.identifier.scopusauthoridHo, MHK=8925896400en_HK
dc.identifier.scopusauthoridChan, GCF=16160154400en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats